Th17 Markers for Acne Diagnosis and Targeted Inhibitor Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acne lack effective targeting of the inflammatory process, particularly involving Th17 cells, which are crucial in the pathogenesis of acne vulgaris, leading to incomplete understanding and inadequate therapeutic options.
Innovation Solution
Identification of IL-12Rβ1/IL-23R, CCR6, BATF, AHR, STAT3, and IRF4 as markers for Th17 cell differentiation, enabling their use in diagnosing acne and screening inhibitors to inhibit Th17 cell differentiation, which can be used in treating acne.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current acne treatments are used, then general anti-inflammatory effects are achieved, but specific targeting of Th17 cell-mediated inflammation is insufficient
Solution Approach 1:
The patent applies local quality by developing treatments specifically targeted at Th17 cell-mediated inflammatory pathways in acne, rather than general anti-inflammatory approaches. This involves identifying and targeting specific molecular markers (IL-12Rβ1, IL-23R, CCR6, STAT3, RORγt) that are locally expressed in Th17 cells within acne lesions, enabling precise intervention in the Th17 inflammatory cascade while sparing other immune pathways.
Solution Approach 2:
The patent employs parameter changes by measuring and monitoring the expression levels of Th17-related markers (IL-12Rβ1, IL-23R, CCR6, STAT3, RORγt mRNA and protein) to characterize acne inflammation and evaluate treatment response. By quantifying these specific parameters, the patent enables objective assessment of Th17 cell activity and treatment efficacy, allowing for personalized treatment adjustments based on measured marker levels.
2Measurement precision
If Th17 cell markers are used for diagnosis, then diagnostic accuracy is improved, but complexity of detection increases
Solution Approach 1:
The patent applies segmentation by dividing the diagnostic process into distinct molecular targets (IL-12Rβ1, IL-23R, CCR6, STAT3, RORγt) that can be detected individually or in combinations. This segmentation allows for stepwise diagnostic approaches where simpler markers can be assessed first, with more complex multi-marker panels used when needed, thereby managing detection complexity while maintaining high diagnostic accuracy.
Solution Approach 2:
The patent employs universality by developing detection methods that can identify multiple Th17 markers simultaneously using common molecular biology techniques (RT-PCR, immunohistochemistry, flow cytometry). These multi-functional assays can detect various Th17-related markers in the same sample using standardized protocols, reducing the need for separate specialized tests for each marker and thereby managing detection complexity.
3Adaptability or versatility
If inhibitors of Th17 differentiation are screened, then therapeutic options are expanded, but screening process complexity increases
Solution Approach 1:
The patent employs intermediaries by using Th17 marker expression levels (IL-12Rβ1, IL-23R, CCR6, STAT3, RORγt) as mediators to screen for inhibitors. Instead of directly testing complex Th17 cell differentiation assays, the patent uses these markers as intermediate readouts that reflect Th17 cell activity and response to potential inhibitors, thereby simplifying the screening process while maintaining the ability to identify effective therapeutic compounds.
Data Source
Figure 1~2
AI summary
The invention is directed to the use of IL-12R 1/IL-23R, CCR6, BATF, AHR, STAT3, IRF4 crucial actors in Thl7 cells differentiation as new markers for acne, and their use to diagnose acne, to screen inhibitors of Th17 differentiation, notably in inhibiting IL-12R 1/IL-23R, CCR6, BATF, AHR, STAT3,IRF4 and the use of these screened inhibitors in acne treatment.